CD200 overexpression has been reported in the CSCs of human papillomavirus (HPV)-positive and HPV-negative head and neck squamous cell carcinomas, thus pointing out its candidacy as a potentially actionable CSC marker [39] and paving the way for new therapeutic approaches targeting this immunomodulation-associated protein [40]. The gene discussed is CD200; the disease is head and neck squamous cell carcinoma.